Cytosorbents (CTSO) Net Cash Flow Growth (5y) (2015 - 2026)
Cytosorbents (CTSO) Net Cash Flow Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 181.39 Bn | 174.10 Bn | 6.27 Bn |
| 2 | Stryker | 128.38 Bn | 125.50 Bn | 3.81 Bn |
| 3 | Medtronic | 107.68 Bn | 98.46 Bn | 6.41 Bn |
| 4 | Boston Scientific | 67.98 Bn | 66.53 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 47.81 Bn | 44.13 Bn | 1.29 Bn |
| 6 | GE HealthCare Technologies | 28.53 Bn | 26.25 Bn | 1.98 Bn |
| 7 | Dexcom | 28.35 Bn | 27.24 Bn | 750.30 Mn |
| 8 | Smith & Nephew | 26.78 Bn | 26.20 Bn | - |
| 9 | Koninklijke Philips | 25.34 Bn | 22.21 Bn | 2.07 Bn |
| 10 | Cytosorbents | 23.46 Mn | 18.66 Mn | 6.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.92% |
| Dec 31, 2025 | 30.67% |
| Sep 30, 2025 | -15.41% |
| Jun 30, 2025 | -16.97% |
| Mar 31, 2025 | -25.19% |
| Dec 31, 2024 | 9.35% |
| Sep 30, 2024 | -56.64% |
| Jun 30, 2024 | 28.29% |
| Mar 31, 2024 | -15.35% |
| Dec 31, 2023 | 33.36% |
| Sep 30, 2023 | -69.54% |
| Jun 30, 2023 | -27.60% |
| Mar 31, 2023 | -23.08% |
| Dec 31, 2022 | -17.97% |
| Sep 30, 2022 | -48.46% |
| Jun 30, 2022 | -24.33% |
| Mar 31, 2022 | -34.95% |
| Dec 31, 2021 | -45.16% |
| Sep 30, 2021 | -14.63% |
| Jun 30, 2021 | -20.86% |